Insmed faced disappointment, then took a deep breath and moved on. After clinical trials of its lead candidate IPLEX fizzled as a potential treatment for myotonic muscular dystrophy, the company regrouped and looked for a new direction. It settled on a merger with Transave, another biopharmaceutical company with an drug candidate in late stage development. Its inhaled ARIKACE is being investigated for the treatment of chronic lung infections in patients with cystic fibrosis. Transave also brought along its eFlow Nebulizer drug delivery technology in development. Insmed is still investigating IPLEX as a treatment for other medical conditions and maintains a preclinical research program for oncology drugs.